INNOVIVA, INC. Effective Income Tax Rate Reconciliation, Deduction, Other, Amount
INNOVIVA, INC. (INVA) reported Effective Income Tax Rate Reconciliation, Deduction, Other, Amount of $15.27 million for the 12-month period ending 2023-12-31, per its 10-K/A filed 2024-03-05.
Discontinued › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationDeductionsOther · last filed 2024-03-05
- INNOVIVA, INC. effective income tax rate reconciliation, deduction, other, amount for fiscal 2023 was $15.27M.
- INNOVIVA, INC. effective income tax rate reconciliation, deduction, other, amount for fiscal 2022 was $0.00.
- INNOVIVA, INC. effective income tax rate reconciliation, deduction, other, amount for fiscal 2021 was $0.00.
| Period end | Effective Income Tax Rate Reconciliation, Deduction, Other, Amount 12 month |
|---|---|
| 2023-12-31 | $15.27M 10-K/A · filed 2024-03-05 |
| 2022-12-31 | $0.00 10-K/A · filed 2024-03-05 |
| 2021-12-31 | $0.00 10-K/A · filed 2024-03-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |